Fenoprofen

drug
On this page

Also known as FenoprofeneFenoprofenoLILLY-53858NSC-757813Progesic

Summary

Fenoprofen (CHEMBL1297) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE04) targeting PTGS1 and SLC5A8; indicated across 1 condition including rheumatic disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: M01AE04
  • Targets: 2 (PTGS1, SLC5A8)
  • Indications: 1 condition
  • Chemistry: 242.27 Da · C15H14O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1297
NameFenoprofen
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID3342
ChEBICHEBI:5004
ATCM01AE04
Molecular formulaC15H14O3
Molecular weight242.27
InChIKeyRDJGLLICXDHJDY-UHFFFAOYSA-N

SMILES: CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O

IUPAC name: 2-(3-phenoxyphenyl)propanoic acid

ChEBI definition: A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, cyclooxygenase 2 inhibitor, cyclooxygenase 1 inhibitor, antipyretic, non-narcotic analgesic, drug allergen.

Also known as: Fenoprofen, Fenoprofene, Fenoprofeno, LILLY-53858, NSC-757813, Progesic, fenoprofen, FENOPROFEN, FENOPROFENE

Parent form; salt/anhydrous children: CHEMBL138241, CHEMBL2068720, CHEMBL2103736

Patent coverage: 13,911 distinct patent families (56,307 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 56,255 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition6.840%P23219
SLC5A8SMCT1Inhibition4.570.2%Q8N695

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PTGS16.84IC50145nMCHEMBL_ACT_7648309
PTGS15.82AC501520nMCHEMBL_ACT_25205452
P059795.56IC502730nMCHEMBL_ACT_18666400

Target pathways

Aggregated over 2 target gene(s): PTGS1, SLC5A8.

Top Reactome pathways

12 total, by targets touching each:

PathwayTargetsGenes
COX reactions1PTGS1
Metabolism1SLC5A8
Nicotinate metabolism1SLC5A8
Metabolism of water-soluble vitamins and cofactors1SLC5A8
Metabolism of vitamins and cofactors1SLC5A8
R-HSA-1972641SLC5A8
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1PTGS1
Transport of small molecules1SLC5A8
R-HSA-4253931SLC5A8
SLC-mediated transmembrane transport1SLC5A8
Organic anion transport by SLC5/17/25 transporters1SLC5A8
SLC-mediated transport of inorganic anions1SLC5A8

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process1
response to oxidative stress1
regulation of blood pressure1
cyclooxygenase pathway1
regulation of cell population proliferation1
long-chain fatty acid biosynthetic process1
lipid metabolic process1
fatty acid metabolic process1
fatty acid biosynthetic process1
prostaglandin metabolic process1
prostanoid biosynthetic process1
cellular oxidant detoxification1
monoatomic ion transport1
sodium ion transport1
chloride transport1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
rheumatic disorder4MONDO:0005554EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

275 molecules share ≥1 primary target. Top 100 by shared-target count:

MoleculeSourceStatusShared targets
KETOPROFENChEMBL + PubChemPhase 4 (approved)PTGS1, SLC5A8
2-MERCAPTOETHANESULFONIC ACIDChEMBLPhase 4 (approved)PTGS1
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1
ACARBOSEChEMBLPhase 4 (approved)PTGS1
ACEMETACINChEMBLPhase 4 (approved)PTGS1
ACETOHYDROXAMIC ACIDChEMBLPhase 4 (approved)PTGS1
ALITRETINOINChEMBLPhase 4 (approved)PTGS1
AMDINOCILLINChEMBLPhase 4 (approved)PTGS1
ARIPIPRAZOLEChEMBLPhase 4 (approved)PTGS1
ASCORBIC ACIDChEMBLPhase 4 (approved)PTGS1
ASPIRINChEMBLPhase 4 (approved)PTGS1
AVATROMBOPAGChEMBLPhase 4 (approved)PTGS1
BELINOSTATChEMBLPhase 4 (approved)PTGS1
BENDAMUSTINEChEMBLPhase 4 (approved)PTGS1
BENZIODARONEChEMBLPhase 4 (approved)PTGS1
BETA CAROTENEChEMBLPhase 4 (approved)PTGS1
BRIGATINIBChEMBLPhase 4 (approved)PTGS1
BROMFENACChEMBLPhase 4 (approved)PTGS1
BROMOCRIPTINEChEMBLPhase 4 (approved)PTGS1
CAPSAICINChEMBLPhase 4 (approved)PTGS1
CAPTOPRILChEMBLPhase 4 (approved)PTGS1
CARBARILChEMBLPhase 4 (approved)PTGS1
CARPROFENChEMBLPhase 4 (approved)PTGS1
CASPOFUNGINChEMBLPhase 4 (approved)PTGS1
CEFPODOXIME PROXETILChEMBLPhase 4 (approved)PTGS1
CELECOXIBChEMBLPhase 4 (approved)PTGS1
CEPHALOGLYCINChEMBLPhase 4 (approved)PTGS1
CEPHALORIDINEChEMBLPhase 4 (approved)PTGS1
CHLORPROTHIXENEChEMBLPhase 4 (approved)PTGS1
CHOLECALCIFEROLChEMBLPhase 4 (approved)PTGS1
CIANIDANOLChEMBLPhase 4 (approved)PTGS1
CLOMIPHENEChEMBLPhase 4 (approved)PTGS1
COLISTINChEMBLPhase 4 (approved)PTGS1
CYCLOSERINEChEMBLPhase 4 (approved)PTGS1
CYSTEINEChEMBLPhase 4 (approved)PTGS1
DACTINOMYCINChEMBLPhase 4 (approved)PTGS1
DELAMANIDChEMBLPhase 4 (approved)PTGS1
DEQUALINIUMChEMBLPhase 4 (approved)PTGS1
DESLORATADINEChEMBLPhase 4 (approved)PTGS1
DESMOPRESSINChEMBLPhase 4 (approved)PTGS1
DESOGESTRELChEMBLPhase 4 (approved)PTGS1
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1
DEXPANTHENOLChEMBLPhase 4 (approved)PTGS1
DEXRAZOXANEChEMBLPhase 4 (approved)PTGS1
DICLOFENACChEMBLPhase 4 (approved)PTGS1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1
DIRITHROMYCINChEMBLPhase 4 (approved)PTGS1
DOPAMINEChEMBLPhase 4 (approved)PTGS1
DOXORUBICINChEMBLPhase 4 (approved)PTGS1
DROXIDOPAChEMBLPhase 4 (approved)PTGS1
EDARAVONEChEMBLPhase 4 (approved)PTGS1
ELIGLUSTATChEMBLPhase 4 (approved)PTGS1
ENASIDENIBChEMBLPhase 4 (approved)PTGS1
EPIRUBICINChEMBLPhase 4 (approved)PTGS1
ERGOCALCIFEROLChEMBLPhase 4 (approved)PTGS1
ERLOTINIBChEMBLPhase 4 (approved)PTGS1
ERTAPENEMChEMBLPhase 4 (approved)PTGS1
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1
ESTRADIOL CYPIONATEChEMBLPhase 4 (approved)PTGS1
ESTRADIOL VALERATEChEMBLPhase 4 (approved)PTGS1
ESTRIOLChEMBLPhase 4 (approved)PTGS1
ETODOLACChEMBLPhase 4 (approved)PTGS1
ETORICOXIBChEMBLPhase 4 (approved)PTGS1
ETRAVIRINEChEMBLPhase 4 (approved)PTGS1
EZETIMIBEChEMBLPhase 4 (approved)PTGS1
FELBINACChEMBLPhase 4 (approved)PTGS1
FENOTEROLChEMBLPhase 4 (approved)PTGS1
FEPRAZONEChEMBLPhase 4 (approved)PTGS1
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)PTGS1
GENTIAN VIOLETChEMBLPhase 4 (approved)PTGS1
GLAFENINEChEMBLPhase 4 (approved)PTGS1
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1
HEXESTROLChEMBLPhase 4 (approved)PTGS1
HYDRALAZINEChEMBLPhase 4 (approved)PTGS1
IBUPROFENChEMBLPhase 4 (approved)PTGS1
IDELALISIBChEMBLPhase 4 (approved)PTGS1
INDIGOTINDISULFONATEChEMBLPhase 4 (approved)PTGS1
INDOMETHACINChEMBLPhase 4 (approved)PTGS1
ISOTRETINOINChEMBLPhase 4 (approved)PTGS1
KETOROLACChEMBLPhase 4 (approved)PTGS1
LATANOPROSTENE BUNODChEMBLPhase 4 (approved)PTGS1
LEVALLORPHANChEMBLPhase 4 (approved)PTGS1
LEVODOPAChEMBLPhase 4 (approved)PTGS1
LEVOMEPROMAZINEChEMBLPhase 4 (approved)PTGS1
LINEZOLIDChEMBLPhase 4 (approved)PTGS1
LOMITAPIDEChEMBLPhase 4 (approved)PTGS1
LOXOPROFENChEMBLPhase 4 (approved)PTGS1
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1
LUSUTROMBOPAGChEMBLPhase 4 (approved)PTGS1
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1
MELOXICAMChEMBLPhase 4 (approved)PTGS1
MELPHALANChEMBLPhase 4 (approved)PTGS1
MEPAZINEChEMBLPhase 4 (approved)PTGS1
MERCAPTOPURINEChEMBLPhase 4 (approved)PTGS1
METAMIZOLEChEMBLPhase 4 (approved)PTGS1
METHICILLINChEMBLPhase 4 (approved)PTGS1
METHIMAZOLEChEMBLPhase 4 (approved)PTGS1